Clinical trials: Atezolizumab
Solid Tumors
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT04250155
- Testing
- XmAb24306, Atezolizumab
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 195 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer Metastatic
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
This is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with…
- Trial name
- NCT05243862
- Testing
- PolyPEPI1018, Atezolizumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Treos Bio Limited
Invasive Ductal Breast Carcinoma
Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
This study that aims to evaluate the addition of MPDL3280A (atezolizumab) to carboplatin and nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast cancer.
- Trial name
- NeoTRIPaPDL1 (NCT02620280)
- Testing
- Carboplatin, Abraxane, MPDL3280A
- Where
- 41 sites in Austria, Germany and 5 more
- Volunteers
- 278 people
- Sponsor
- Fondazione Michelangelo
Head and Neck Neoplasms
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
This proof-of-concept study aims to assess the clinical and biological effects of Atezolizumab combined with Bevacizumab in advanced previously treated squamous-cell carcinoma of the head and neck (HNSCC).
- Trial name
- ATHENA (NCT03818061)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 7 sites in France
- Volunteers
- 33 people
- Sponsor
- Centre Leon Berard
Breast Cancer, Radiotherapy; Complications
Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).
- Trial name
- COMBaRT (NCT07021911)
- Testing
- Radiotherapy
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Ovarian Neoplasms
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
This is a randomized phase II study, aimed at evaluating the efficacy (through progression free survival at 6 months) and safety of 5 different treatments involving atezolizumab, bevacizumab and/or acetylsalicylic acid in…
- Trial name
- NCT02659384
- Testing
- Bevacizumab, atezolizumab, acetylsalicylic acid
- Where
- 12 sites in France, Netherlands and 3 more
- Volunteers
- 122 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis
Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy
A multicentre, parallel group, randomized controlled Phase II clinical trial evaluating neoadjuvant Atezolizumab/Bevacizumab versus neoadjuvant SBRT in patients with biopsy proven solitary HCC with PVTT involving the portal vein…
- Trial name
- ADVANCE HCC (NCT05137899)
- Testing
- Neoadjuvant
- Where
- 7 sites in Canada
- Volunteers
- 1 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by…
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT05168163
- Testing
- Atezolizumab, Cabozantinib, Lenvatinib
- Where
- 16 sites in United States
- Volunteers
- 122 people
- Sponsor
- Academic and Community Cancer Research United
Non-Small Cell Lung Cancer (NSCLC)
Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1
Importance: EGFR tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 immune checkpoint inhibitors are widely used in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT07036016
- Testing
- EGFR-TKI, PD-1/PD-L1 inhibitor, EGFR-TKI combined with PD-1/PD-L1
- Volunteers
- 67,818 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Melanoma, Head and Neck Cancer
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
The purpose of this study is to evaluate the safety of sequential intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol®) for…
- Conditions
- Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
- Trial name
- Poly-ICLC (NCT02423863)
- Testing
- Hiltonol
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Oncovir, Inc.
Metastatic Esophageal Cancer, Metastatic Gastric Cancer
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with advanced unresectable or metastatic OGA who…
- Trial name
- NCT04166721
- Testing
- Atezolizumab
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Urothelial Carcinoma
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
This is a single arm Phase II study with a safety run-in to identify the recommended phase II dose of the combination therapy of atezolizumab and guadecitabine.
- Trial name
- NCT03179943
- Testing
- Atezolizumab, Guadecitabine
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Fox Chase Cancer Center
Lung Neoplasm Malignant
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of…
- Trial name
- BUDDY (NCT04059887)
- Testing
- Atezolizumab Injection [Tecentriq]
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chonnam National University Hospital
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
This phase II trial tests whether nivolumab and ipilimumab works to shrink tumors in patients with liver cancer that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05199285
- Testing
- Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Academic and Community Cancer Research United
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 243 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer, Ovarian Neoplasms
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance…
- Trial name
- AdORN (NCT03394885)
- Testing
- Atezolizumab, Carboplatin, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
This phase II trial tests how well diclofenac works in treating patients non-small cell lung cancer (NSCLC) that may have spread from where it first started (primary site) to other places in the body (metastatic) on single agent…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06731270
- Testing
- Atezolizumab, Biospecimen Collection, Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Hepatocellular Carcinoma, Atezolizumab-bevacizumab
Ate-Bev Early Response Prediction Model in Advanced HCC
The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation
- Trial name
- NCT05763277
- Testing
- Early response evaluation
- Where
- South Korea
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with…
- Trial name
- SKYSCRAPER-14 (NCT05904886)
- Testing
- Atezolizumab, Bevacizumab, Tiragolumab
- Where
- 171 sites in United States, Belgium and 25 more
- Volunteers
- 687 people
- Sponsor
- Hoffmann-La Roche